4D Molecular Therapeutics, Inc. (FDMT)

Market Cap	214.50M
Revenue (ttm)	17,000
Net Income (ttm)	-143.48M
Shares Out	46.23M
EPS (ttm)	-2.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	551,750
Open	4.740
Previous Close	4.670
Day's Range	4.530 - 4.780
52-Week Range	4.405 - 36.250
Beta	2.79
Analysts	Buy
Price Target	36.33 (+682.97%)
Earnings Date	Mar 3, 2025

About FDMT

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macul...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 147
• Stock Exchange: NASDAQ
• Ticker Symbol: FDMT

Financial Performance

In 2023, 4D Molecular Therapeutics's revenue was $20.72 million, an increase of 562.29% compared to the previous year's $3.13 million. Losses were -$100.84 million, -6.19% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is $36.33, which is an increase of 682.97% from the latest price.

Price Target

$36.33

(682.97% upside)

Analyst Consensus: Buy